JP2012532600A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532600A5
JP2012532600A5 JP2012519079A JP2012519079A JP2012532600A5 JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5 JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5
Authority
JP
Japan
Prior art keywords
item
amino acids
isolated
seq
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012519079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532600A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/001962 external-priority patent/WO2011004263A2/en
Publication of JP2012532600A publication Critical patent/JP2012532600A/ja
Publication of JP2012532600A5 publication Critical patent/JP2012532600A5/ja
Withdrawn legal-status Critical Current

Links

JP2012519079A 2009-07-07 2010-07-07 保存された大腸菌免疫原 Withdrawn JP2012532600A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22366409P 2009-07-07 2009-07-07
US61/223,664 2009-07-07
US29114009P 2009-12-30 2009-12-30
US61/291,140 2009-12-30
PCT/IB2010/001962 WO2011004263A2 (en) 2009-07-07 2010-07-07 Conserved escherichia coli immunogens

Publications (2)

Publication Number Publication Date
JP2012532600A JP2012532600A (ja) 2012-12-20
JP2012532600A5 true JP2012532600A5 (enExample) 2013-08-15

Family

ID=43429616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519079A Withdrawn JP2012532600A (ja) 2009-07-07 2010-07-07 保存された大腸菌免疫原

Country Status (12)

Country Link
US (1) US10988511B2 (enExample)
EP (1) EP2451833B1 (enExample)
JP (1) JP2012532600A (enExample)
CN (1) CN102666571A (enExample)
AU (1) AU2010269961A1 (enExample)
CA (1) CA2767536A1 (enExample)
ES (1) ES2662716T3 (enExample)
IL (1) IL217412A0 (enExample)
MX (1) MX2012000395A (enExample)
SG (1) SG177533A1 (enExample)
WO (1) WO2011004263A2 (enExample)
ZA (1) ZA201200412B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
EP3169699A4 (en) * 2014-07-18 2018-06-20 The University of Washington Cancer vaccine compositions and methods of use thereof
US10799573B2 (en) * 2016-03-30 2020-10-13 Regents Of The University Of Minnesota Pertussis vaccines and methods of making and using
AU2018217441B2 (en) * 2017-02-13 2024-11-07 Alexandre Eduardo NOWILL Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
EP3841119A4 (en) 2018-08-23 2022-05-18 La Trobe University COMPOSITIONS AND METHODS FOR REDUCING BACTERIAL AGGREGATION
WO2020240268A1 (en) * 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
WO2021185969A1 (en) * 2020-03-18 2021-09-23 Numaferm Gmbh Variants of hlya and uses thereof
EP3892290A1 (en) * 2020-04-08 2021-10-13 NUMAFERM GmbH Variants of hlya and uses thereof
CN115466732B (zh) * 2021-06-10 2024-09-03 宁夏医科大学 用于制备Hispidin的重组蛋白及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
JPH04500203A (ja) 1988-08-25 1992-01-16 ザ リポソーム カンパニー,インコーポレイテッド インフルエンザワクチンおよび新規なアジュバント
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE190354T1 (de) 1990-12-20 2000-03-15 Arch Dev Corp The University O Kontrolle der genexpression durch ionisierende strahlung
ATE229943T1 (de) 1991-03-01 2003-01-15 Minnesota Mining & Mfg Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
CA2330610A1 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2002018383A2 (en) 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2002255798A1 (en) 2001-04-03 2002-10-21 Biosynexus Incorporated An animal model for enteric pathogens
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
NZ533628A (en) 2001-11-27 2006-07-28 Anadys Pharmaceuticals Inc 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
JP2005533057A (ja) 2002-06-13 2005-11-04 ニューヨーク・ユニバーシティ 合成c−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成c−糖脂質の使用
ATE477251T1 (de) 2002-08-23 2010-08-15 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US20060089264A1 (en) * 2004-02-24 2006-04-27 Seungok Hong Method of heat treating HTc conductors in a large fabricated system
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
NZ561042A (en) 2005-02-18 2011-03-31 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
US8148055B2 (en) * 2006-06-30 2012-04-03 Infineon Technologies Ag Method for developing a photoresist
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
US9173954B2 (en) * 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins

Similar Documents

Publication Publication Date Title
JP2012532600A5 (enExample)
Ren et al. Design and evaluation of a multi-epitope assembly peptide vaccine against Acinetobacter baumannii infection in mice
Leiman et al. Contractile tail machines of bacteriophages
Drake et al. The product of the pilQ gene is essential for the biogenesis of type IV pili in Neisseria gonorrhoeae
JP2014504851A5 (enExample)
NO810803L (no) Fremgangsmaate for fremstilling av et forut bestemt protein ved hjelp av gram-positive bakterier
CN101012458A (zh) 表达系统
Smit et al. Structural and functional analysis of the S-layer protein crystallisation domain of Lactobacillus acidophilus ATCC 4356: evidence for protein–protein interaction of two subdomains
Kobierecka et al. Cell wall anchoring of the Campylobacter antigens to Lactococcus lactis
US12296000B2 (en) SLAM polynucleotides and polypeptides and uses thereof
Kumar et al. Structural analysis and cross-protective efficacy of recombinant 87 kDa outer membrane protein (Omp87) of Pasteurella multocida serogroup B: 2
Messner et al. Occurrence, structure, chemistry, genetics, morphogenesis, and functions of S-layers
JP2012532626A5 (enExample)
Nye et al. Vibrio cholerae H‐NS domain structure and function with respect to transcriptional repression of ToxR regulon genes reveals differences among H‐NS family members
AU739641B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
CN105073989A (zh) 免疫原性多肽表层表达双歧杆菌
EP2920203B1 (en) Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits
WO2012037779A1 (zh) 融合蛋白SAmB及其编码基因与应用
US20050025787A1 (en) Transformed bacteria producing CS6 antigens as vaccines
CN103436550B (zh) 一种菌影载体的构建方法
Kuebutornye et al. Molecular cloning and bioinformatics analysis of t3ss inner membrane ring hrpq from Vibrio harveyi
CN103910785B (zh) 一种荧光假单胞菌TonB依赖型外膜受体及其应用
Miao et al. HpaXm from Xanthomonas citri subsp. malvacearum is a novel harpin with two heptads for hypersensitive response
JP6590916B2 (ja) 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト
CN115057945B (zh) 一种杂合抗菌肽NK-LPd及其基因、载体、制备方法和应用